Skip to main content

Methylin

(methylphenidate hydrochloride, immediate-release)

Methylin (methylphenidate hydrochloride, immediate-release); CII

Full Prescribing Information DailyMed Drug Information

Summary

Methylin is immediate-release methylphenidate supplied as a grape-flavoured oral solution, approved for ADHD in patients 6 years and older and for narcolepsy, with generic chewable tablets at 2.5 mg, 5 mg and 10 mg. Its differentiator is dose granularity for a child who cannot swallow: the solution measures to fractions of a milligram, which no tablet in the class can do. Schedule II; oral solution brand and generic, chewable tablet generic only.

Forms & Strengths

  • Oral solution (grape, colorless): 5 mg/5 mL and 10 mg/5 mL
  • Chewable tablets (grape): 2.5 mg, 5 mg, 10 mg

Dosing

  • Age:
    • ADHD: >= 6y
    • Narcolepsy: no age floor
  • Onset: ~ 1 hour
  • Duration: 3 to 4 hours
  • Initial Dose:
    • >= 6 y/o and older: 5 mg twice daily, before breakfast and before lunch
    • Adults: 20 to 30 mg daily in 2 or 3 divided doses, 30 to 45 minutes before meals.
  • Titration: 5 - 10 mg every 7 days
  • Max Dose: 60 mg/day
  • Considerations: The chewable tablet must be taken with at least 8 ounces of fluid because it swells and can cause choking, and it contains phenylalanine.

Pharmacology

  • Mechanism: Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses
  • Delivery / Release: Immediate release, no modified-release component in either form. Solution and IR tablet are near-bioequivalent at 20 mg.
  • Metabolism: De-esterified to ritalinic acid, essentially inactive. Protein binding 10% to 33%. Mean terminal half-life 2.7 hours, the shortest methylphenidate in this library.
  • Food effect: a high-fat meal raises solution Cmax ~13% and AUC ~25% and delays Tmax by about an hour, a smaller effect than on Metadate CD.
  • Class Positioning: The only methylphenidate titratable in fractions of a milligram, and the most reversible. Compare Ritalin (IR tablet) and QuilliChew ER, an extended-release chewable not to be confused with this one.

Indications

  • ADHD (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients 6 y/o and older, and adults
  • Narcolepsy (ICD-10: G47.419): no age floor

Off-Label Uses

  • ADHD in children 4 to 5 years old (ICD-10: F90.x): behavioral therapy first line; IR methylphenidate from a low dose where it fails. Expert consensus. (AAP 2019)
  • Afternoon top-up alongside a long-acting methylphenidate (ICD-10: F90.x): coherent given the 3 to 4 hour window; 60 mg/day ceiling applies to the sum. Limited data. (AHRQ 2024)
  • Where the evidence does not support use: binge eating disorder (F50.2), treatment-resistant depression (F33.9), cancer-related and other fatigue (R53.0, R53.83). Adult literature only; insufficient in children. (AHRQ 2024)
  • Cognitive enhancement in a youth without ADHD: not an indication and not supported.

Contraindications & Warnings

  • Boxed Warning: Abuse, misuse and addiction, with overdose and death; risk rises with dose and non-oral routes. Assess abuse risk before prescribing and reassess throughout.
  • Contraindicated:
    • Hypersensitivity to methylphenidate or any component
    • MAOI use, current or within 14 days: hypertensive crisis
    • Chewable tablet only: difficulty swallowing. Use the oral solution.
  • Use with caution:
    • Structural cardiac abnormality, cardiomyopathy, serious arrhythmia or coronary disease: avoid
    • Pre-existing hypertension: monitor blood pressure and pulse
    • Psychotic or bipolar disorder: exacerbation and treatment-emergent mania
    • Significant hyperopia or angle-closure risk: refer to ophthalmology
    • Personal or family history of tics or Tourette's syndrome
    • Phenylketonuria, chewable only: 0.42 / 0.84 / 1.68 mg phenylalanine per 2.5 / 5 / 10 mg tablet
    • Substance use disorder in patient or household; a 500 mL CII bottle is hard to audit
  • Screen before starting:
    • Cardiac history and exam including family sudden death; the label requires the screen, not an ECG
    • Tics, mania risk factors, and abuse or diversion risk in patient and household
    • Swallowing ability, which decides the form; PKU if a chewable is considered
    • Baseline height, weight, BP and HR

Drug Interactions

  • MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days.
  • Antihypertensives: effectiveness reduced. Increase BP monitoring and adjust the antihypertensive.
  • Halogenated anesthetics (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold all doses on the day of surgery.
  • Risperidone: EPS may increase when either dose changes in either direction. Monitor across any titration.
  • Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only. Counsel on symptoms rather than avoiding.
  • Venlafaxine: one pediatric NMS-like report after a first dose. Watch the first days of any new serotonergic agent.

Administration

  • Give 30 to 45 minutes before meals, which is a labeled instruction.
  • Before breakfast and before lunch; add a third dose for afternoon coverage. Last dose before 6 p.m. if sleep is affected.
  • Oral solution: measure with an oral syringe or calibrated cup, never a kitchen spoon. The two strengths look identical; state the concentration on every prescription.
  • Chewable tablet: chew well, swallow with at least 8 ounces of fluid; it swells and can obstruct the throat.
  • Missed dose: give only if the next is several hours away and it is not late. Never double up.
  • Store locked. A flavoured CII liquid is the form a younger sibling is likeliest to drink.

Side Effects

  • Common: tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, decreased appetite, weight loss, dry mouth, nausea, abdominal pain. No pediatric percentages published.
  • Serious:
    • Choking or esophageal obstruction from a chewable taken dry: emergency, unique to that form
    • Sudden death with structural cardiac disease: avoid in that population
    • New psychosis or mania, including with no psychiatric history: consider discontinuing
    • Priapism, sometimes surgical, including during drug holidays and withdrawal
    • Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit
    • Long-term growth suppression; angle-closure glaucoma; new or worsening tics
    • Postmarketing: seizures, dyskinesia, cerebral arteritis, hepatic injury, leukopenia, thrombocytopenic purpura, erythema multiforme, rhabdomyolysis, NMS

Monitoring & Labs

  • Concentration and measuring device: confirm at every visit and refill; the twofold strength difference is this page's likeliest dosing error.
  • Adherence: confirm at every visit that the midday dose is given; a missed school dose mimics loss of efficacy.
  • Growth: height, weight and BMI at baseline and every 6 months; every visit if losing weight.
  • Cardiovascular: BP and HR at baseline, at every dose change, and at least every 6 months.
  • Appetite and sleep: at every visit and dose change; ask the time of the last dose.
  • Psychiatric and tics: screen for psychosis, mania, aggression, depressed mood and tics at baseline and every visit.
  • Abuse and diversion: at every refill, ask about sharing and selling and check the PDMP. Reconcile volume remaining against days elapsed; a bottle cannot be pill-counted.
  • Laboratory: none required. Check liver enzymes only for jaundice, dark urine or unexplained abdominal pain.

Discontinuation & Taper

  • No taper required; neither label gives a tapering schedule.
  • Discontinue if no improvement after appropriate dose adjustment over one month.
  • Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite.
  • Priapism has occurred during drug holidays and on discontinuation.
  • Drug holidays are easiest here: the solution can be part-dosed as well as part-scheduled.

Pregnancy & Lactation

  • Pregnancy: no drug-associated risk of major birth defects or miscarriage identified. Stimulant vasoconstriction may reduce placental perfusion. Background risk 2% to 4% and 15% to 20%. Weigh against untreated maternal ADHD.
  • Lactation: infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant plasma in every reported case. Not a reason to stop breastfeeding. (LactMed 2025)
  • Lactation, milk supply: prolactin falls; large doses may interfere before supply is established. Monitor the infant for agitation, insomnia and poor weight gain. (LactMed 2025)
  • Exposure Registry: National Pregnancy Registry for Psychostimulants, 1-866-961-2388.

Counseling Points

  • Counsel the family on:

    • The two concentrations: the same 5 mL is 5 mg or 10 mg depending on the bottle. Check every refill, and measure only with the supplied syringe.
    • The chewable needing a full 8 ounce glass every time; chewed dry it swells and can block the throat.
    • The 3 to 4 hour window: the lunchtime dose is part of the plan, not a sign the first failed.
    • Rebound irritability and hunger several times a day: expected, not a reason to raise the dose.
    • Locking up the bottle; a flavoured CII liquid is the easiest form to lose unnoticed.
    • Bringing a teacher rating scale, morning and afternoon rated separately.

  • Advise them to call for:

    • Chest pain, vomiting or trouble swallowing after a chewable: emergency
    • Chest pain, fainting, or a racing heart that does not settle
    • New hallucinations, or new suspicious or fearful thinking
    • Numbness, coldness or colour change in fingers or toes, or a sore that will not heal
    • A new or markedly worse tic, including throat clearing and blinking
    • A painful erection lasting more than a few hours, including during a break
    • Any amount of the solution swallowed by another child in the house

References

  1. DailyMed. Methylin (methylphenidate hydrochloride) oral solution prescribing information. Shionogi Inc. 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e3c22d9-71d9-46a7-b315-8021c94c4bec
  2. DailyMed. Methylphenidate hydrochloride chewable tablets prescribing information. Lupin Pharmaceuticals. 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bfe50ed-171f-4c40-bc0b-20c68e8e2025
  3. FDA. openFDA National Drug Code Directory, generic_name methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22methylphenidate%22&limit=1000
  4. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/
  5. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/
  6. AHRQ. Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/
Back to top